CONTACT A REP
Patients HCP
This site is for US Health Care Professionals only.

About GEP-NET Patients

Identifying Patients for LUTATHERA

LUTATHERA can be used to treat SSTR+ GEP-NETs in the foregut, midgut, and hindgut1

Choose early LUTATHERA for your patients who are newly diagnosed or have progressed on an SSA1-3

LUTATHERA is for patients with newly diagnosed GEP-NETs1,3

Consider these characteristics

Consider these characteristics for patients with newly diagnosed GEP-NETs: a diagnosis of well-differentiated, SSTR+, metastatic or locally advanced, inoperable GEP-NETs; who are newly diagnosed (within the last 6 months); with a Ki-67 index ≥10% and ≤55% and marked as grade 2 or 3; any GEP-NET primary site; and a Karnofsky Performance Score ≥60.

LUTATHERA is for patients with GEP-NETs after SSA progression1,2

Consider these characteristics

Consider these characteristics for patients with GEP-NETs after SSA progression: a diagnosis of well-differentiated, SSTR+, metastatic or locally advanced, inoperable GEP-NETs; who have had any prior disease progression while on an SSA; with a Ki-67 index ≤20% and marked as grade 1 or 2; any GEP-NET primary site; and a Karnofsky Performance Score ≥60.

Which of your patients is ready to start strong with LUTATHERA?

1L, first line; 2L, second line; 3L, third line; GEP-NETs, gastroenteropancreatic neuroendocrine tumors; SSA, somatostatin analogue; SSTR+, somatostatin receptor-positive.
References: 1. Lutathera. Prescribing information. Novartis Pharmaceuticals Corp. 2. Strosberg J, El-Haddad G, Wolin E, et al; for the NETTER-1 trial investigators. Phase 3 trial of 177Lu-dotatate for midgut neuroendocrine tumors. N Engl J Med. 2017;376(2):125-135. 3. Singh S, Halperin D, Myrehaug S, et al. [177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high-dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2-3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study. Lancet. 2024;403(10446):2807-2817.